Winter Rheumatology Symposium
About the Event
Date:To Be Announced
Location:Snowmass, CO
Credit:TBA
On Demand:To Be Announced
Registration Coming Soon
The Winter Rheumatology Symposium (WRS) provides up-to-date, practical clinical information on the diagnosis and management of patients with rheumatic and immune disorders.
Target Audience
Rheumatologists, members of the interprofessional team, and other healthcare providers who care for patients with rheumatic diseases and those interested or engaged in research in the field of rheumatology.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize and manage complex rheumatic diseases (e.g., rheumatoid arthritis, lupus erythematosus, Sjögren’s disease, vasculitis)
- Implement evidence-based treatment approaches for autoimmune and inflammatory diseases
- Demonstrate the impact and utility of AI in the rheumatology space
- Utilize collaboration and co-management of patients with obesity and other comorbidities as they relate to rheumatologic conditions
- Apply the most recent guidelines in the management of rheumatologic conditions, such as lupus nephritis
For information about the previous meeting, see the Winter Rheumatology Symposium 2026 section below.
Program Schedule & Syllabi
To Be Announced
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
Registration Fees
To Be Announced
Registration Guidelines
To Be Announced
Hotel and Travel
To Be Announced
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
CE
CE Accreditation Statement
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Provider Number: 0003797.
AMA Designation Statement
The American College of Rheumatology designates this Live Activity for a maximum of to be announced) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
See the ACR’s CE Mission Statement. For more information, download the AMA PRA Booklet.
CE credit must be claimed by (to be announced).
MOC
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to (to be announced) MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CE activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
MOC points must be claimed by (to be announced).
Instructions to Claim CE/MOC Credit
Credit claiming is available after the activity starts.
See instructions to claim credit on the CE & MOC page.
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Education (CE) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CE activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CE activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
WRS 2027 Financial Relationships Disclosures to be announced.
The Winter Rheumatology Symposium 2026 was an in-person only event held from January 25–29, 2026, in Snowmass Village, CO.
The Winter Rheumatology Symposium (WRS) provides up-to-date, practical clinical information on the diagnosis and management of patients with rheumatic and immune disorders.
Target Audience
Rheumatologists, members of the interprofessional team, and other healthcare providers who care for patients with rheumatic diseases and those interested or engaged in research in the field of rheumatology.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize and manage complex rheumatic diseases (e.g., rheumatoid arthritis, lupus erythematosus, Sjögren’s disease, vasculitis)
- Implement evidence-based treatment approaches for autoimmune and inflammatory diseases
- Demonstrate the impact and utility of AI in the rheumatology space
- Utilize collaboration and co-management of patients with obesity and other comorbidities as they relate to rheumatologic conditions
- Apply the most recent guidelines in the management of rheumatologic conditions, such as lupus nephritis
Program Schedule & Syllabi
Winter Rheumatology Symposium 2026 Program Schedule
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
CE
CE Accreditation Statement
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Provider Number: 0003797.
AMA Designation Statement
The American College of Rheumatology designates this Live Activity for a maximum of 20.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
See the ACR’s CE Mission Statement. For more information, download the AMA PRA Booklet.
CE credit must be claimed by March 30, 2026.
MOC
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 20.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CE activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
MOC points must be claimed by March 30, 2026.
Instructions to Claim CE/MOC Credit
Credit claiming is available after the activity starts.
See instructions to claim credit on the CE & MOC page.
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Education (CE) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CE activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CE activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
WRS 2026 Financial Relationships Disclosures >
Acknowledgement of Commercial Support
We gratefully acknowledge that the 2026 Winter Rheumatology Symposium is supported in part by an unrestricted educational grant from the following commercial supporter. We extend our sincere thanks to this organization for their generous contributions: Janssen Scientific Affairs, LLC.